Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2016

Date: July 27, 2016
Pages: 86
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R0F7568D245EN
Leaflet:

Download PDF Leaflet

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2016

SUMMARY

Global Markets Direct’s, ‘Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2016’, provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease)
  • The report reviews pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics and enlists all their major and minor projects
  • The report assesses Reflux Esophagitis (Gastroesophageal Reflux Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Reflux Esophagitis (Gastroesophageal Reflux Disease)
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview
Therapeutics Development
Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Overview
Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Development by Companies
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics under Investigation by Universities/Institutes
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Development by Companies
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Products under Investigation by Universities/Institutes
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Companies Involved in Therapeutics Development
Ahn-Gook Pharmaceutical Co., Ltd.
Alveonix AG
Cempra, Inc.
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Ironwood Pharmaceuticals, Inc.
Jeil Pharmaceutical Co., Ltd.
Johnson & Johnson
RaQualia Pharma Inc.
Vecta Ltd.
Wockhardt Limited
Yuyu Pharma, Inc.
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(lansoprazole + omeprazole) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ax-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEM-031 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-1367 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
E-3710 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
esomeprazole magnesium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-17DT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IW-3718 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-26070109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JP-1366 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
netazepide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omeprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pantoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Block Proton Pump for Gastrointestinal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Tubulin for Barrett's Esophageal Adenocarcinoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tegoprazan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tenatoprazole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-2A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YY-DXR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Product Development Milestones
Featured News & Press Releases
Mar 23, 2016: Ironwood Pharmaceuticals Initiates Phase IIb Clinical Trial of IW-3718 in Refractory Gastroesophageal Reflux Disease
Feb 18, 2016: RaQualia Receives a Patent Allowance for Acid Pump Antagonist in Korea
Oct 19, 2015: Ironwood Highlights Refractory GERD Research at the American College of Gastroenterology 2015 Annual Scientific Meeting
Feb 04, 2015: Ironwood Reports Positive Top-Line Data from Exploratory Phase IIa Trial Of IW-3718 in Refractory Gastroesophageal Reflux Disease
Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease
Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision
Mar 29, 2011: RaQualia Pharma Announces Successful Results From Phase I Study Of Acid Pump Antagonist
Apr 01, 2010: Santarus Announces Launch of ZEGERID OTC by Schering-Plough Consumer HealthCare
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
Dec 22, 2009: Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC
Dec 05, 2009: Santarus Receives FDA Approval for Immediate-Release Omeprazole
Dec 01, 2009: Santarus Announces FDA Approval of Schering-Plough HealthCare Products' ZEGERID OTC
Oct 26, 2009: Santarus To Present Positive Data From Two Investigator-Initiated Studies With ZEGERID At ACG 2009 Meeting
Oct 12, 2009: Santarus and Norgine Enter License for ZEGERID Immediate-Release Omeprazole Products in Europe
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2016
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Alveonix AG, H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Cempra, Inc., H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Eisai Co., Ltd., H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Johnson & Johnson, H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by RaQualia Pharma Inc., H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Vecta Ltd., H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Wockhardt Limited, H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline by Yuyu Pharma, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects, H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects (Contd..1), H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Dormant Projects (Contd..2), H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products, H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products (Contd..1), H2 2016
Reflux Esophagitis (Gastroesophageal Reflux Disease) - Discontinued Products (Contd..2), H2 2016

LIST OF FIGURES

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H2 2016
Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease) - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

COMPANIES MENTIONED

Ahn-Gook Pharmaceutical Co., Ltd.
Alveonix AG
Cempra, Inc.
Daewoong Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Ironwood Pharmaceuticals, Inc.
Jeil Pharmaceutical Co., Ltd.
Johnson & Johnson
RaQualia Pharma Inc.
Vecta Ltd.
Wockhardt Limited
Yuyu Pharma, Inc.
Skip to top


Alzheimer's Disease - Pipeline Review, H2 2016 US$ 2,500.00 Aug, 2016 · 1284 pages
Huntington's Disease - Pipeline Review, H2 2015 US$ 1,700.00 Nov, 2015 · 311 pages

Ask Your Question

Reflux Esophagitis (Gastroesophageal Reflux Disease) - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: